CS logo
small CS logo
Semmelweis University Heart and Vascular Center

Budapest, Hungary
Egyetem, Budapest

About Semmelweis University Heart and Vascular Center


A Városmajori Szív- és Érgyógyászati Klinika Budapest XII. kerülete egyik kórháza, a magyarországi szívátültetés központja. A Semmelweis Egyetem oktatóintézménye.
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender

Clinical Trials at Semmelweis University Heart and Vascular Center


During the past decade, Semmelweis University Heart and Vascular Center conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 3 clinical trials were completed, i.e. on average, 8.1% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 3 clinical trials were completed. i.e. 18.8% of trials that started reached the finish line.

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Semmelweis University Heart and Vascular Center" #1 sponsor was "Semmelweis University Heart and Vascular Center" with 11 trials, followed by "BackBeat Medical Inc" with 4 trials sponsored, "Amgen" with 2 trials sponsored, "Kinepict Health Ltd." with 2 trials sponsored and "Abbott Medical Devices" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 27 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis University Heart and Vascular Center" #1 collaborator was "Semmelweis University" with 3 trials as a collaborator, "MLM Medical Labs GmbH" with 2 trials as a collaborator, "Massachusetts General Hospital" with 2 trials as a collaborator, "University of Debrecen" with 2 trials as a collaborator and "nabios GmbH" with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 32 trials.

Clinical Trials Conditions at Semmelweis University Heart and Vascular Center


According to Clinical.Site data, the most researched conditions in "Semmelweis University Heart and Vascular Center" are "Heart Failure" (5 trials), "Myocardial Infarction" (4 trials), "Acute Myocardial Infarction" (2 trials), "Atrial Fibrillation" (2 trials) and "Atrioventricular Block" (2 trials). Many other conditions were trialed in "Semmelweis University Heart and Vascular Center" in a lesser frequency.

Clinical Trials Intervention Types at Semmelweis University Heart and Vascular Center


Most popular intervention types in "Semmelweis University Heart and Vascular Center" are "Device" (15 trials), "Drug" (12 trials), "Procedure" (7 trials), "Diagnostic Test" (2 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (7 trials), "14 day Holter ECG" (1 trials), "App measurement" (1 trials), "CPNS Therapy" (1 trials) and "CRT-D" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Semmelweis University Heart and Vascular Center


The vast majority of trials in "Semmelweis University Heart and Vascular Center" are 42 trials for "All" genders.

Clinical Trials Status at Semmelweis University Heart and Vascular Center


Currently, there are NaN active trials in "Semmelweis University Heart and Vascular Center". undefined are not yet recruiting, 12 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Semmelweis University Heart and Vascular Center, undefined suspended trials, and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Semmelweis University Heart and Vascular Center, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 17 trials that are defined as “Not Applicable".